Study on PD-L1 Expression in NSCLC Patients and Related Influencing Factors in the Real World

PD-L1 is one of the current biomarkers for immune checkpoint inhibitor (ICI) therapy in patients with non-small-cell lung cancer. However, the expression of PD-L1 in the real world and its related influencing factors remain unclear. We want to observe the expression of PD-L1 in the real world and st...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Yefei, Lin, Shuangxiang, Wang, Yueping, Shen, Bingxiao, Lin, Ling, Wang, Liangxing, He, Susu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727119/
https://www.ncbi.nlm.nih.gov/pubmed/34992670
http://dx.doi.org/10.1155/2021/3273347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727119/
https://www.ncbi.nlm.nih.gov/pubmed/34992670
http://dx.doi.org/10.1155/2021/3273347

Ejemplares similares